Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
14 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03839771 | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy(HOVON150AML) | active not recruiting | Phase 3 | 968 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 15 | Sep 22, 2026 | clinicaltrials |
| NCT01208766 | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma(HO95) | completed |
| Phase 3 |
| 1,503 |
| Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER |
| 16 |
| Jan 6, 2026 |
| clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT02737501 | ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants(ALTA-1L) | completed | Phase 3 | 275 | Ariad PharmaceuticalsINDUSTRY | 19 | Aug 20, 2021 | clinicaltrials |
| NCT01235962 | A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)(PROTECT) | completed | Phase 3 | 1,538 | Novartis PharmaceuticalsINDUSTRY | 26 | Nov 23, 2020 | clinicaltrials |
| NCT02785900 | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia(CASCADE) | terminated | Phase 3 | 240 | Seagen Inc.INDUSTRY | 16 | Dec 12, 2018 | clinicaltrials |
| NCT01154140 | A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung(PROFILE 1014) | completed | Phase 3 | 343 | PfizerINDUSTRY | 31 | Nov 6, 2017 | clinicaltrials |
| NCT00182819 | Radiation Therapy or Temozolomide in Treating Patients With Gliomas | completed | Phase 3 | 709 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 19 | Oct 12, 2016 | clinicaltrials |
| NCT00021450 | Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer | completed | Phase 3 | 819 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Sep 2, 2016 | clinicaltrials |
| NCT01082549 | Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)(ECLIPSE) | completed | Phase 3 | 780 | SanofiINDUSTRY | 14 | Mar 17, 2016 | clinicaltrials |
| NCT01254279 | Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen | completed | Phase 3 | 984 | SanofiINDUSTRY | 29 | Jan 21, 2015 | clinicaltrials |
| NCT00038467 | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer(IES) | completed | Phase 3 | 4,740 | PfizerINDUSTRY | 37 | May 7, 2014 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials